# A Study to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia Not Adequately Controlled on Statin Therapy

Study · id `cardio:ct-nct04669041` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04669041](<https://clinicaltrials.gov/study/NCT04669041>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04669041

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 305 participants.

## Technical summary

Registry record NCT04669041. Randomized; triple masking; primary purpose treatment. Start 2020-12-08 (actual); primary completion 2022-06-15 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 305 participants (enrolled count; ClinicalTrials.gov record NCT04669041, source copy `cardio:ctgov-nct04669041-2025-09-22`, retrieved 2026-10-31)
- Started: 2020-12-08 (actual) (ClinicalTrials.gov record NCT04669041, source copy `cardio:ctgov-nct04669041-2025-09-22`, retrieved 2026-10-31)
- Primary completion: 2022-06-15 (actual) (ClinicalTrials.gov record NCT04669041, source copy `cardio:ctgov-nct04669041-2025-09-22`, retrieved 2026-10-31)
- Completion: 2022-06-15 (actual) (ClinicalTrials.gov record NCT04669041, source copy `cardio:ctgov-nct04669041-2025-09-22`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT04669041, source copy `cardio:ctgov-nct04669041-2025-09-22`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04669041-2025-09-22`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia Not Adequately Controlled on Statin Therapy
- Acronym: ROZEL
- Condition: Hypercholesterolemia
- Intervention (Drug): Rosuvastatin
- Intervention (Drug): SPC ezetimibe/rosuvastatin
- Intervention (Drug): Rosuvastatin active capsule
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Rosuvastatin (`cardio:rosuvastatin`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and Safety of Single-Pill Combination of Rosuvastatin and Ezetimibe in Chinese Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Treatment (ROZEL): A Randomized, Double-Blind, Double Dummy, Active-Controlled Phase 3 Clinical Trial (`cardio:pubmed-37770770`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 089280f0b73e2f5bc8e06538b96b0e03b7afa6cde6c0209088b784395ee95401
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
